Early Life Exposure to Human Milk Oligosaccharides Reduces Allergic Response in a Murine Asthma Model
Journal of Immunology Research · 2023
DOI: 10.1155/2023/9603576 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Immunology Research, 2023. Verfasst von Tahereh Bozorgmehr und 6 weiteren Autor:innen. Beteiligte Einrichtung: Michael Smith Laboratories, University of British Columbia, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Food Hypersensitivity, Asthma, Gastrointestinal Microbiome. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Abbott Nutrition, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Background
Studies suggest that early-life gut microbiota composition and intestinal short-chain fatty acids (SCFAs) are linked to future asthma susceptibility. Furthermore, infancy offers a critical time window to modulate the microbiota and associated metabolites through diet-microbe interactions to promote infant health. Human milk oligosaccharides (HMOs), nondigestible carbohydrates abundant in breast milk, are prebiotics selectively metabolized by gut microbiota that consequently modify microbiome composition and SCFA production.
Methods
Using a house dust mite mouse model of allergy, we investigated the impacts of early oral treatment of pups with biologically relevant doses of 2′-fucosyllactose (2′-FL) and 6′-sialyllactose (6′-SL), two of the most abundant HMOs in human milk, in amelioration of allergic airway disease severity.
Results
We found that administration of 2′-FL and 6′-SL during early life reduced lung histopathology scores, circulating IgE, cytokine levels, and inflammatory cell infiltration, all hallmark symptoms of allergic asthma. HMO supplementation also increased the relative abundance of intestinal Bacteroidetes and Clostridia, known SCFA producers within the gut. Indeed, we detected increased SCFA concentrations in both the intestine and blood of adult mice who received HMOs prior to weaning.
Conclusion
We propose a model in which orally administered HMOs delivered during early life shift the microbiota toward increased production of SCFAs, which dampens the allergic immune responses behind allergy and asthma. Overall, these data suggest the potential for HMO supplementation to protect infants against asthma development later in life, with possible benefits against additional atopic diseases such as eczema and food allergies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Michael Smith Laboratories, University of British Columbia, Vancouver, BC, Canada.
- Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada.
- Nutrition Division, Abbott Laboratories, Columbus, OH, USA.
- Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, Canada.
ORCID-Profile: Tahereh Bozorgmehr, Rozlyn C T Boutin, Sarah E Woodward, Katherine Donald, Jo May Chow, Rachael H Buck, B Brett Finlay
Förderung
- Abbott Nutrition
- Canadian Institutes of Health Research
Zitieren
APA
Bozorgmehr, T., Boutin, R. C. T., Woodward, S. E., Donald, K., Chow, J. M., Buck, R. H., & Finlay, B. B. (2023). Early Life Exposure to Human Milk Oligosaccharides Reduces Allergic Response in a Murine Asthma Model. Journal of Immunology Research. https://doi.org/10.1155/2023/9603576
Vancouver
Bozorgmehr T, Boutin RCT, Woodward SE, Donald K, Chow JM, Buck RH, et al. Early Life Exposure to Human Milk Oligosaccharides Reduces Allergic Response in a Murine Asthma Model. Journal of Immunology Research. 2023. doi:10.1155/2023/9603576
BibTeX
@article{Bozorgmehr2023,
author = {Bozorgmehr, Tahereh and Boutin, Rozlyn C T and Woodward, Sarah E and Donald, Katherine and Chow, Jo May and Buck, Rachael H and Finlay, B Brett},
title = {Early Life Exposure to Human Milk Oligosaccharides Reduces Allergic Response in a Murine Asthma Model},
journal = {Journal of Immunology Research},
year = {2023},
doi = {10.1155/2023/9603576}
}
EUVIMED